Overview

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Kartos Therapeutics, Inc.
Treatments:
Trametinib